MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Clinical Trial Progress: MapLight Therapeutics' ZEPHYR trial is accelerating enrollment, with topline results for 300 schizophrenia patients now expected in Q3 2026, showcasing the company's efficient execution under high-quality standards.
- IRIS Trial Update: The IRIS trial has completed enrollment, with topline results for approximately 160 autism patients also anticipated in Q3 2026, further enhancing the company's research capabilities in central nervous system disorders.
- Strategic Commitment: CEO Chris Kroeger emphasized that the rapid enrollment pace not only narrows timing guidance but also demonstrates the company's commitment to advancing its programs, potentially boosting investor confidence and attracting more funding support.
- Market Potential: With a focus on developing drugs for mental health disorders, MapLight is positioned to fill the market gap for specific therapies as clinical trials progress, driving future business growth.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on MPLT
Wall Street analysts forecast MPLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MPLT is 31.00 USD with a low forecast of 28.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.580
Low
28.00
Averages
31.00
High
34.00
Current: 18.580
Low
28.00
Averages
31.00
High
34.00
About MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
- IPO Market Recovery: Aktis Oncology launched a $200 million IPO on Monday, indicating a resurgence in the biotech IPO market after a period of uneven performance, and is set to be the first significant IPO of 2026.
- Increased Financing Size: Just two days after the IPO launch, Aktis upsized the deal by 50%, which not only reflects growing investor confidence in its prospects but also indicates a rising interest in the biotech sector.
- Strategic Partnership Support: Aktis disclosed a $100 million investment from partner Eli Lilly, which will provide robust support for the company's R&D and market expansion, further strengthening its position in the competitive biotech landscape.
- Optimistic Market Outlook: As the first major biotech IPO of 2026, Aktis's success could attract more investor attention to the biotech sector, potentially driving recovery and growth across the industry.
Continue Reading
MapLight Accelerates Phase 2 Trial Timelines for Schizophrenia and Autism Studies
- Clinical Trial Progress: MapLight Therapeutics' ZEPHYR trial is accelerating enrollment, with topline results for 300 schizophrenia patients now expected in Q3 2026, showcasing the company's efficient execution under high-quality standards.
- IRIS Trial Update: The IRIS trial has completed enrollment, with topline results for approximately 160 autism patients also anticipated in Q3 2026, further enhancing the company's research capabilities in central nervous system disorders.
- Strategic Commitment: CEO Chris Kroeger emphasized that the rapid enrollment pace not only narrows timing guidance but also demonstrates the company's commitment to advancing its programs, potentially boosting investor confidence and attracting more funding support.
- Market Potential: With a focus on developing drugs for mental health disorders, MapLight is positioned to fill the market gap for specific therapies as clinical trials progress, driving future business growth.
Continue Reading